Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry

Despite the increasing number of cases of secondary antibody deficiency (SAD) and immunoglobulin (Ig) utilization, there is a paucity of data in the literature on clinical and patient-reported outcomes in this population. To describe immunoglobulin utilization patterns, clinical and patient-reported...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2023-11, Vol.18 (11), p.e0294408-e0294408
Main Authors: Abadeh, Armin, Shehadeh, Sarah, Betschel, Stephen, Waserman, Susan, Cameron, Donald William, Cowan, Juthaporn
Format: Article
Language:English
Subjects:
Antibodies
Bacterial infections
Bronchitis
Care and treatment
Chemotherapy
Chronic lymphocytic leukemia
Clinical outcomes
Clinical trials
Comorbidity
Data analysis
Demographics
Emergency medical care
Emergency medical services
Evidence-based medicine
Health aspects
Hospitalization
Immunoglobulins
Infection
Infections
Intravenous administration
Leukemia
Lymphoma
Medical research
Medicine, Experimental
Multiple myeloma
Patient compliance
Patient outcomes
Patients
Pharmaceutical industry
Pneumonia
Questionnaires
Sinusitis
Viral antibodies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the increasing number of cases of secondary antibody deficiency (SAD) and immunoglobulin (Ig) utilization, there is a paucity of data in the literature on clinical and patient-reported outcomes in this population. To describe immunoglobulin utilization patterns, clinical and patient-reported outcomes in patients with SAD on immunoglobulin replacement therapy (IgRT). A cross-sectional study of patients with secondary antibody deficiency enrolled in the Ontario Immunoglobulin Treatment (ONIT) Case Registry from June 2020 to September 2022 was completed. Demographics, comorbidities, indications for immunoglobulin treatment, clinical infections at baseline and post IgRT, and patient-reported outcomes were collected and analyzed. There were 140 patients (58 males; 82 females; median age 68) with SAD during the study period; 131 were on subcutaneous Ig (SCIG) and 9 were on intravenous Ig (IVIG). The most common indication was chronic lymphocytic leukemia (CLL) (N = 52). IgRT reduced the average annual number of infections by 82.6%, emergency room (ER) visits by 84.6%, and hospitalizations by 83.3%. Overall, 84.6% of patients reported their health as better compared to before IgRT. Among those patients who switched from IVIG to SCIG (N = 35), 33.3% reported their health as the same, and 62.9% reported their health as better. This study demonstrates that IgRT significantly improved clinical outcomes and patient-reported general health state in patients with SAD. This study also further supports the use of SCIG in patients with SAD.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0294408